Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Motoo Nagane, MD PhD, Yoshitaka Narita, MD PhD, Kazuhiko Mishima, MD PhD, Yasuhito Terui, MD PhD, Yoshiki Arakawa, MD PhD, Hajime Yonezawa, MD PhD, Katsunori Asai, MD PhD, Noriko Fukuhara, MD PhD, Kazuhiko Sugiyama, MD PhD, Naoki Shinojima, MD PhD, Junsaku Kitagawa, Arata Aoi, Ryo Nishikawa, MD PhD

Blood (2019) 134 (Supplement_1): 1586.

https://doi.org/10.1182/blood-2019-123362

Published: 2019

Journal Articles

Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia

Wataru Munakata, Naohiro Sekiguchi, MD PhD, Rai Shinya, MD,PhD, Kenshi Suzuki, MD PhD, Hiroshi Handa, MD PhD, Hirohiko Shibayama, MD PhD, Tomoyuki Endo, MD PhD, Yasuhito Terui, MD PhD, Noriko Iwaki, MD PhD, Noriko Fukuhara, MD PhD, Hiro Tatetsu, MD PhD, Shinsuke Iida, MD PhD, Takayuki Ishikawa, MD PhD, Ryota Shiibashi, Koji Izutsu, MD PhD

Blood (2019) 134 (Supplement_1): 345.

https://doi.org/10.1182/blood-2019-124614

Published: 2019

Journal Articles

Safety, Phamacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study

Tim Somervaille, MD PhD, Olga Salamero, MD, Pau Montesinos, MD PhD, Christophe Willekens, MD, Jose Antonio Perez Simon, MD, Arnaud Pigneux, MD, Christian Recher, MD PhD, Rakesh Popat, Cesar Molinero, MD PhD, Christina Mascaro, PhD, Tamara Maes, PhD, Francesc Bosch, MD PhD

Blood (2016) 128 (22): 4060.

https://doi.org/10.1182/blood.V128.22.4060.4060

Published: 2016

Journal Articles

Skin Rash with Eosinophilia Resulting from Bendamustine Plus Rituximab Treatment: A Hematological and Pathological Analysis of 5 Cases

Tatsuro Jo, MD PhD, Kensuke Horio, MD, Kazuto Shigematsu, MD PhD, Fumi Toriyama, MD

Blood (2014) 124 (21): 5376.

https://doi.org/10.1182/blood.V124.21.5376.5376

Published: 2014

Journal Articles

Nilotinib Following Molecular Suboptimal Response (SoR) To Imatinib In Japanese Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): 12 Month Follow-Up From The SENSOR Study

Blood (2013) 122 (21): 2729.

https://doi.org/10.1182/blood.V122.21.2729.2729

Published: 2013

Journal Articles

Novel AKT Inhibitor Afuresertib In Combination With Bortezomib and Dexamethasone Demonstrates Favorable Safety Profile and Significant Clinical Activity In Patients With Relapsed/Refractory Multiple Myeloma

Peter M Voorhees, Andrew Spencer, MD, Heather J. Sutherland, MD, PhD, FRCPC, Michael E O'Dwyer, MD, FRCPI, FRCPath, Shang-Yi Huang, MD, PhD, Keith Stewart, MBA, MB, CHB, Ajai Chari, MD, Michael Rosenzwieg, MD, Ajay K. Nooka, MD, MPH, Cara A Rosenbaum, MD, Craig C Hofmeister, MD, Deborah A Smith, PharmD, Joyce M Antal, Ademi Santiago-Walker, Jennifer Gauvin, Joanna B Opalinska, Suzanne Trudel, MD

Blood (2013) 122 (21): 283.

https://doi.org/10.1182/blood.V122.21.283.283

Published: 2013

Journal Articles

Successful Tolerance of Deferasirox Following Desensitization for Significant Skin Rash

Hatoon Ezzat, MBBS, FRCP, ABIM, R. Robert Schellenberg, Heather A Leitch, MD, PhD, FRCPC, Linda M Vickars, MD, FRCP(C)

Blood (2011) 118 (21): 5280.

https://doi.org/10.1182/blood.V118.21.5280.5280

Published: 2011

Journal Articles

Paraneoplastic Pemphigus (PNP) As a Presenting Finding in a Patient with Hodgkin's Lymphoma

Philip Marjon, MD, Byung Kim, MD, Tamara Lazic, MD, Christina Cernik, MD, Ritesh Rathore, MD

Blood (2011) 118 (21): 4864.

https://doi.org/10.1182/blood.V118.21.4864.4864

Published: 2011

Journal Articles

Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt – Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002

David A. Rizzieri, MD, Jeffrey L Johnson, John C. Byrd, MD, Gerard Lozanski, MD, Bayard L. Powell, MD, Thomas C. Shea, MD, Sreenivasa Nattom, Eva Hoke, Bruce D. Cheson, MD, Richard Larson, M.D.

Blood (2010) 116 (21): 858.

https://doi.org/10.1182/blood.V116.21.858.858

Published: 2010

Journal Articles

Phase II Trial of Lenalidomide in Patients with Relapsed or Refractory Hodgkin Lymphoma

John Kuruvilla, MD, Diane Taylor, Lisa Wang, Chantale Blattler, Armand Keating, MD, Michael Crump, MD

Blood (2008) 112 (11): 3052.

https://doi.org/10.1182/blood.V112.11.3052.3052

Published: 2008

NARROW

Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia

Safety, Phamacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study

Skin Rash with Eosinophilia Resulting from Bendamustine Plus Rituximab Treatment: A Hematological and Pathological Analysis of 5 Cases

Nilotinib Following Molecular Suboptimal Response (SoR) To Imatinib In Japanese Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): 12 Month Follow-Up From The SENSOR Study

Novel AKT Inhibitor Afuresertib In Combination With Bortezomib and Dexamethasone Demonstrates Favorable Safety Profile and Significant Clinical Activity In Patients With Relapsed/Refractory Multiple Myeloma

Successful Tolerance of Deferasirox Following Desensitization for Significant Skin Rash

Paraneoplastic Pemphigus (PNP) As a Presenting Finding in a Patient with Hodgkin's Lymphoma

Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt – Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002

Phase II Trial of Lenalidomide in Patients with Relapsed or Refractory Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only